Geron Corporation (GERN) Soars After Study Shows Bone Marrow Drug's Benefit
12/6/2013 7:40:27 AM
Geron Corp. (GERN) shares rose as much as 32 percent after a Mayo Clinic study found the biotechnology company’s experimental drug imetelstat helped patients with a bone marrow cancer. Geron increased 17 percent to $6.86 at 7:57 a.m. New York time after gaining to $7.73. The Menlo Park, California-based company’s shares had climbed more than three-fold this year through yesterday.
Help employers find you! Check out all the jobs and post your resume.
comments powered by